Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 43% Improvement Relative Risk Serrano et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 22 patients in Spain Lower mortality with HCQ (not stat. sig., p=0.15) Serrano et al., Ann. Oncol., 2020, Sep, 31, S1026, doi:10.1016/j.annonc.2020.08.1830 Favors HCQ Favors control
COVID-19 and lung cancer: What do we know?
Serrano et al., Ann. Oncol., 2020, Sep, 31, S1026, doi:10.1016/j.annonc.2020.08.1830
Serrano et al., COVID-19 and lung cancer: What do we know?, Ann. Oncol., 2020, Sep, 31, S1026, doi:10.1016/j.annonc.2020.08.1830
Sep 2020   Source   PDF  
  All Studies   Meta
Small retrospective study of 22 lung cancer patients, 14 treated with HCQ+AZ, showing HCQ+AZ mortality relative risk RR 0.57, p = 0.145.
risk of death, 43.0% lower, RR 0.57, p = 0.14, treatment 6 of 14 (42.9%), control 6 of 8 (75.0%), NNT 3.1.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Serrano et al., 22 Sep 2020, retrospective, Spain, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Annals of Oncology 1765P abstracts Developing a risk assessment score for cancer patients during the COVID-19 pandemic A. Indini, M. Cattaneo, M. Ghidini, E. Rijavec, C. Bareggi, B. Galassi, D. Gambini, F. Grossi Medical Oncology Unit, Ospedale Maggiore Policlinico-Fondazione IRCCS Ca’ Granda, Milan, Italy Background: Data on the novel coronavirus (CoV) respiratory disease (COVID-19) in cancer patients (pts) are limited. In some individuals, CoV infection triggers an aberrant inflammatory response, leading to lung tissue damage. Cancer pts treated with immunotherapy (IT) may therefore be more at risk for COVID-19 infection and related complications. Methods: We performed a thorough review of the literature on CoV pathogenesis and cancer, selecting shared features of the two disease entities to develop a riskassessment score to quantify both the risk of infection and the risk implied in cancer treatment delays. Results: The score includes clinical and laboratory variables (Table). Pts’ characteristics include: age, presence of comorbidities (hypertension, cardiovascular disease, diabetes, chronic obstructive pulmonary disease, chronic systemic infections), obesity, sex, Eastern Cooperative Oncology Group (ECOG) performance status (PS), and concomitant steroid treatment (>10 mg daily of prednisone equivalent, lasting for >1-month period). Disease characteristics include: lung cancer diagnosis, history of thoracic radiotherapy (RT) (only for pts with extra-thoracic tumours). Treatment characteristics include: line of treatment, type (IT or combined IT/chemotherapy [CT] considered high-risk, followed by CT, and other anticancer drugs), history of immunerelated adverse events (irAEs). Laboratory tests include: levels of neutrophil-to-lymphocite ratio (NLR), lactate-dehydrogenase (LDH), and C-reactive protein (CRP). Based on the resulting score, pts can be divided in the following categories of risk: low (score <4), intermediate (score 4-6), and high risk (score >7). Table: 1765P The “Milano Policlinico ONCOVID Score” for risk evaluation in oncology during COVID-19 Variables Score Sex ECOG PS Age BMI Comorbidities Concomitant steroid treatment Thoracic tumour History of thoracic RT Line of cancer treatment Type of treatment F¼0M¼1 0 - 1 ¼ 0 2, or higher ¼ 1 < 70 ¼ 0 70, or higher ¼ 1 < 30 ¼ 0 30, or higher ¼ 1 NO ¼ 0 YES ¼ 1 Yes, >1 ¼ 2 NO ¼ 0 YES ¼ 1 History of irAEs NLR LDH CRP NO ¼ 0 YES ¼ 1 NO ¼ 0 YES ¼ 1 adjuvant ¼ 0 1st, or more ¼ 1 hormone therapy, targeted therapy, monoclonal antibodies ¼ 0 CT ¼ 1 IT/IT + CT ¼ 2 NO ¼ 0 YES ¼ 1 YES, pneumonitis ¼ 2 < 5 ¼ 0 5, or higher ¼ 1 < ULN ¼ 0 ULN, or higher ¼ 1 < ULN ¼ 0 ULN, or higher ¼ 1 Conclusions: There is a strong rationale supporting the presented data as potential risk factors for COVID-19 in cancer pts. The present score is currently undergoing validation on a wide population of cancer pts to confirm its role and potentially help physicians’ treatment decisions. Legal entity responsible for the study: The authors. 1766P COVID-19 and lung cancer: What do we know? G. Serrano, J. Rogado, C. Pangua, B. Obispo, A. Martin Marino, M. Perez-Perez, A. Lopez-Alfonso, M.A. Lara Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain Background: Currently we still have limited information on how COVID-19 infection has affected lung cancer patients. In our study, we analysed whether there are differences in terms of mortality from COVID-19 between patients..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop